View Financial HealthQuest PharmaTech 配当と自社株買い配当金 基準チェック /06Quest PharmaTech配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 02Quest PharmaTech Inc., Annual General Meeting, Aug 25, 2025Quest PharmaTech Inc., Annual General Meeting, Aug 25, 2025. Location: alberta, edmonton CanadaNew Risk • Sep 27New major risk - Revenue and earnings growthEarnings have declined by 40% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (76% average weekly change). Earnings have declined by 40% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$4.23m market cap, or US$3.13m).お知らせ • Aug 13Quest PharmaTech Inc., Annual General Meeting, Oct 08, 2024Quest PharmaTech Inc., Annual General Meeting, Oct 08, 2024. Location: hybrid meeting, Canadaお知らせ • May 31Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of DirectorsQuest PharmaTech Inc. announced the appointment of Mr. Bradley J. Glass to the Board of Directors, subject to regulatory approval. Mr. Glass has served as the General Counsel of Hepalink USA Inc. and its subsidiaries ("Hepalink") for the past two years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues, including matters involving contracts, employment, intellectual property, litigation, tax, insurance, regulatory compliance, and permitting. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of sophisticated regulatory and business matters.Board Change • Apr 01Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 4 highly experienced directors. 2 independent directors (4 non-independent directors). CEO & Director Madi Madiyalakan is the most experienced director on the board, commencing their role in 2004. Independent Director John Lievonen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jan 24Quest PharmaTech Inc. Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical StudyQuest PharmaTech Inc. announced that it has received information that the Phase III clinical trial of oregovomab for the treatment of Ovarian Cancer, sponsored by CanariaBio Inc. ("CAB"), has received recommendations from the Data Safety Monitoring Board (DSMB), an independent committee appointed by CAB to advise on the trials, to discontinue the clinical trial after conducting a futility evaluation for interim progression free survival in study subjects. The DSMB also expressed the opinion that due to the characteristics of immunotherapy drugs, there is a possibility of significant efficacy in overall survival and recommended that follow up observations be continued in study subjects. Quest holds bonds of Korea-based OQP Bio Inc. (the "OQP Bonds") received in connection with the sale of the immunotherapy technology assets, including oregovomab, of investee company OncoQuest Inc. in April 2020. Quest continues to pursue the monetization of the OQP Bonds and is currently engaged in discussions with CanariaBio M Co. Ltd. ("CABM"), the parent company of OQP Bio as well as KOSDAQ listed CAB. The OQP Bonds are currently illiquid and there can be no assurance that the Company will be successful in negotiating monetization terms with CABM for its OQP Bio bonds, that any definitive agreement will be entered into for such monetization, or that the Company will ultimately be able to monetize all or any part of its bonds. Quest is also in discussions with CABM on options available for Quest to continue to support the oregovomab clinical program.Board Change • Nov 09Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 4 highly experienced directors. 2 independent directors (4 non-independent directors). CEO & Director Madi Madiyalakan is the most experienced director on the board, commencing their role in 2004. Independent Director John Lievonen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Aug 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 4 highly experienced directors. 2 independent directors (4 non-independent directors). CEO & Director Madi Madiyalakan is the most experienced director on the board, commencing their role in 2004. Independent Director John Lievonen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jul 12Quest PharmaTech Inc. Provides Product Development UpdateQuest PharmaTech Inc. announced that a U.S patent has been granted to its lead product candidate MAb AR 9.6 that will protect many isoforms of monoclonal antibody including IgE and its AllergoOncology Technology. MAb AR 9.6 licensed from University of Nebraska Medical Centre binds to a novel tumor associated marker (truncated O-Glycan bearing MUC16) and has potential use in targeted cancer therapy for pancreatic, ovarian and breast cancer. MAb AR 9. 6 blocks the activation of growth factor receptors and thereby inhibits phosphorylation of Akt, which leads to reduced cell proliferation, in vivo tumor growth and metastasis. Quest has also established and validated the tumor-targeting ability of AR9.6 as a promising theranostic agent in animal models for immuno-positron emission tomography, fluorescence guided surgery and radioimmunotherapy. This lead product has already generated six manuscripts in peer reviewed journals and two U.S patents, and the program is in the late preclinical stage. Quest is a pioneer in the field of monoclonal antibody-based cancer therapy and has developed the antibody-based immunotherapy technology by using very low dose murine monoclonal antibodies against secreted tumor associated antibodies to stimulate the immune system to fight against cancer. The antibody technology was transferred to OncoQuest, in which Quest presently holds a 42.5% ownership interest, in 2015 for further development and was subsequently purchased by a Korean-based company pursuant to an asset transfer agreement in April 2020. The antibody immunotherapy using oregovomab is now being developed by Korea-based CanariaBio Co Ltd. which has recently completed the enrollment of 602 patients in its Phase III clinical study (FLORA-5; QPT-ORE-005; GOG-3035; NCT04498117) with participation of 163 sites across 16 countries.お知らせ • May 13Quest PharmaTech Inc., Annual General Meeting, Jul 13, 2023Quest PharmaTech Inc., Annual General Meeting, Jul 13, 2023.お知らせ • Sep 29Sang Ho Jang agreed to acquire unknown minority take in Bioceltran Co., Ltd from Quest PharmaTech Inc. (TSXV:QPT) for CAD 0.3 million.Sang Ho Jang agreed to acquire unknown minority take in Bioceltran Co., Ltd from Quest PharmaTech Inc. (TSXV:QPT) for CAD 0.3 million on September 28, 2022. Quest PharmaTech will receive an upfront payment of CAD 0.1 million upon agreement execution and a second and final payment of CAD 0.2 million within 12 months. As part of the transaction, the PDT technology license agreement with Bioceltran for the SL017 and SL052 technologies will be terminated so that Quest has full control on the future development of the technology.お知らせ • May 20Quest PharmaTech Inc., Annual General Meeting, Jul 19, 2022Quest PharmaTech Inc., Annual General Meeting, Jul 19, 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Shawn Lu was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Executive Departure • Jul 13Independent Director William Meekison has left the companyOn the 5th of July, William Meekison's tenure as Independent Director ended after 3.7 years in the role. We don't have any record of a personal shareholding under William's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 16.50 years.Executive Departure • Jul 13Independent Director Bin Huang has left the companyOn the 5th of July, Bin Huang's tenure as Independent Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Bin's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 16.50 years.Is New 90 Day High Low • Dec 16New 90-day high: CA$0.24The company is up 71% from its price of CA$0.14 on 17 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 15% over the same period.決済の安定と成長配当データの取得安定した配当: QPTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: QPTの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Quest PharmaTech 配当利回り対市場QPT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (QPT)n/a市場下位25% (CA)1.7%市場トップ25% (CA)5.4%業界平均 (Biotechs)2.4%アナリスト予想 (QPT) (最長3年)n/a注目すべき配当: QPTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: QPTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: QPTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: QPTが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YCA 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 12:37終値2026/05/22 00:00収益2025/10/31年間収益2025/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Quest PharmaTech Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 02Quest PharmaTech Inc., Annual General Meeting, Aug 25, 2025Quest PharmaTech Inc., Annual General Meeting, Aug 25, 2025. Location: alberta, edmonton Canada
New Risk • Sep 27New major risk - Revenue and earnings growthEarnings have declined by 40% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (76% average weekly change). Earnings have declined by 40% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$4.23m market cap, or US$3.13m).
お知らせ • Aug 13Quest PharmaTech Inc., Annual General Meeting, Oct 08, 2024Quest PharmaTech Inc., Annual General Meeting, Oct 08, 2024. Location: hybrid meeting, Canada
お知らせ • May 31Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of DirectorsQuest PharmaTech Inc. announced the appointment of Mr. Bradley J. Glass to the Board of Directors, subject to regulatory approval. Mr. Glass has served as the General Counsel of Hepalink USA Inc. and its subsidiaries ("Hepalink") for the past two years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues, including matters involving contracts, employment, intellectual property, litigation, tax, insurance, regulatory compliance, and permitting. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of sophisticated regulatory and business matters.
Board Change • Apr 01Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 4 highly experienced directors. 2 independent directors (4 non-independent directors). CEO & Director Madi Madiyalakan is the most experienced director on the board, commencing their role in 2004. Independent Director John Lievonen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 24Quest PharmaTech Inc. Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical StudyQuest PharmaTech Inc. announced that it has received information that the Phase III clinical trial of oregovomab for the treatment of Ovarian Cancer, sponsored by CanariaBio Inc. ("CAB"), has received recommendations from the Data Safety Monitoring Board (DSMB), an independent committee appointed by CAB to advise on the trials, to discontinue the clinical trial after conducting a futility evaluation for interim progression free survival in study subjects. The DSMB also expressed the opinion that due to the characteristics of immunotherapy drugs, there is a possibility of significant efficacy in overall survival and recommended that follow up observations be continued in study subjects. Quest holds bonds of Korea-based OQP Bio Inc. (the "OQP Bonds") received in connection with the sale of the immunotherapy technology assets, including oregovomab, of investee company OncoQuest Inc. in April 2020. Quest continues to pursue the monetization of the OQP Bonds and is currently engaged in discussions with CanariaBio M Co. Ltd. ("CABM"), the parent company of OQP Bio as well as KOSDAQ listed CAB. The OQP Bonds are currently illiquid and there can be no assurance that the Company will be successful in negotiating monetization terms with CABM for its OQP Bio bonds, that any definitive agreement will be entered into for such monetization, or that the Company will ultimately be able to monetize all or any part of its bonds. Quest is also in discussions with CABM on options available for Quest to continue to support the oregovomab clinical program.
Board Change • Nov 09Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 4 highly experienced directors. 2 independent directors (4 non-independent directors). CEO & Director Madi Madiyalakan is the most experienced director on the board, commencing their role in 2004. Independent Director John Lievonen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Aug 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 4 highly experienced directors. 2 independent directors (4 non-independent directors). CEO & Director Madi Madiyalakan is the most experienced director on the board, commencing their role in 2004. Independent Director John Lievonen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jul 12Quest PharmaTech Inc. Provides Product Development UpdateQuest PharmaTech Inc. announced that a U.S patent has been granted to its lead product candidate MAb AR 9.6 that will protect many isoforms of monoclonal antibody including IgE and its AllergoOncology Technology. MAb AR 9.6 licensed from University of Nebraska Medical Centre binds to a novel tumor associated marker (truncated O-Glycan bearing MUC16) and has potential use in targeted cancer therapy for pancreatic, ovarian and breast cancer. MAb AR 9. 6 blocks the activation of growth factor receptors and thereby inhibits phosphorylation of Akt, which leads to reduced cell proliferation, in vivo tumor growth and metastasis. Quest has also established and validated the tumor-targeting ability of AR9.6 as a promising theranostic agent in animal models for immuno-positron emission tomography, fluorescence guided surgery and radioimmunotherapy. This lead product has already generated six manuscripts in peer reviewed journals and two U.S patents, and the program is in the late preclinical stage. Quest is a pioneer in the field of monoclonal antibody-based cancer therapy and has developed the antibody-based immunotherapy technology by using very low dose murine monoclonal antibodies against secreted tumor associated antibodies to stimulate the immune system to fight against cancer. The antibody technology was transferred to OncoQuest, in which Quest presently holds a 42.5% ownership interest, in 2015 for further development and was subsequently purchased by a Korean-based company pursuant to an asset transfer agreement in April 2020. The antibody immunotherapy using oregovomab is now being developed by Korea-based CanariaBio Co Ltd. which has recently completed the enrollment of 602 patients in its Phase III clinical study (FLORA-5; QPT-ORE-005; GOG-3035; NCT04498117) with participation of 163 sites across 16 countries.
お知らせ • May 13Quest PharmaTech Inc., Annual General Meeting, Jul 13, 2023Quest PharmaTech Inc., Annual General Meeting, Jul 13, 2023.
お知らせ • Sep 29Sang Ho Jang agreed to acquire unknown minority take in Bioceltran Co., Ltd from Quest PharmaTech Inc. (TSXV:QPT) for CAD 0.3 million.Sang Ho Jang agreed to acquire unknown minority take in Bioceltran Co., Ltd from Quest PharmaTech Inc. (TSXV:QPT) for CAD 0.3 million on September 28, 2022. Quest PharmaTech will receive an upfront payment of CAD 0.1 million upon agreement execution and a second and final payment of CAD 0.2 million within 12 months. As part of the transaction, the PDT technology license agreement with Bioceltran for the SL017 and SL052 technologies will be terminated so that Quest has full control on the future development of the technology.
お知らせ • May 20Quest PharmaTech Inc., Annual General Meeting, Jul 19, 2022Quest PharmaTech Inc., Annual General Meeting, Jul 19, 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Shawn Lu was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Executive Departure • Jul 13Independent Director William Meekison has left the companyOn the 5th of July, William Meekison's tenure as Independent Director ended after 3.7 years in the role. We don't have any record of a personal shareholding under William's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 16.50 years.
Executive Departure • Jul 13Independent Director Bin Huang has left the companyOn the 5th of July, Bin Huang's tenure as Independent Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Bin's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 16.50 years.
Is New 90 Day High Low • Dec 16New 90-day high: CA$0.24The company is up 71% from its price of CA$0.14 on 17 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 15% over the same period.